Abstract
Although severe atopic dermatitis (SAD) represent less than 20% of all patients with atopic dermatitis, in this subgroup of subjects quality of life is markedly disturbed. As real-world data concerning dupilumab in patients with SAD are currently scarce, we investigated the early effect of dupilumab in a selected SAD cohort in a real-world background.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
